Triple-negative breast cancer (TNBC) is a heterogeneous group of breast cancers, characterized by lack of expression of estrogen receptors, progesterone receptors and human epidermal growth factor receptor 2 gene amplification, making it unresponsive to endocrine therapy and HER2-targeted treatment. This evidence concerns the gene ESR1 and breast carcinoma.